Literature DB >> 19255850

Clinical outcomes of patients with ulcerative colitis and co-existing Clostridium difficile infection.

Daniela Jodorkovsky1, Yuki Young, Maria T Abreu.   

Abstract

BACKGROUND: The incidence of Clostridium difficile infection is increasing in the United States. The aim of our investigation is to compare short-term and long-term outcomes of patients admitted with an ulcerative colitis (UC) flare and co-existent C. difficile infection to those of non-infected patients.
METHODS: A historical cohort study was undertaken examining admissions at Mount Sinai Hospital between June 2004 and June 2005 using ICD-9 criteria for UC. Charts were abstracted for those patients for whom C. difficile testing was performed.
RESULTS: Of 288 admissions, 99 charts met the inclusion criteria. Fifty-two patients were C. difficile-negative and 47 were positive. Demographic data and laboratory values upon admission did not differ between the two groups. Patients who were C. difficile-positive had significantly more UC-related hospitalizations and emergency room visits in the year following initial admission (58 visits vs. 27, P = 0.001 and eight visits vs. 1 visit (P = 0.012), respectively). One year following the index admission, C. difficile patients had significantly higher rates of colectomy compared to C. difficile-negative patients (44.6% vs. 25%, P = 0.04). Length of hospitalization (11.7 vs. 11 days), use of cyclosporine therapy during index admission (48% vs. 47% of patients), and percentage requiring colectomy at initial admission (23.4% vs. 13.5%) did not reach statistical significance.
CONCLUSIONS: Our data suggest that patients presenting with a UC flare who are infected with C. difficile have worse long-term clinical outcomes than those that are C. difficile-negative. C. difficile testing should be performed for all patients presenting with UC flare. Further studies are warranted to elucidate how infection can alter the natural history of UC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19255850     DOI: 10.1007/s10620-009-0749-9

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  16 in total

1.  Secular trends in hospital-acquired Clostridium difficile disease in the United States, 1987-2001.

Authors:  Lennox K Archibald; Shailen N Banerjee; William R Jarvis
Journal:  J Infect Dis       Date:  2004-04-20       Impact factor: 5.226

2.  Incidence of Clostridium difficile infection in inflammatory bowel disease.

Authors:  Joseph F Rodemann; Erik R Dubberke; Kimberly A Reske; Da Hea Seo; Christian D Stone
Journal:  Clin Gastroenterol Hepatol       Date:  2007-03       Impact factor: 11.382

3.  Evaluation of three rapid assays for detection of Clostridium difficile toxin A and toxin B in stool specimens.

Authors:  H Rüssmann; K Panthel; R-C Bader; C Schmitt; R Schaumann
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-02       Impact factor: 3.267

Review 4.  Clostridium difficile colitis.

Authors:  C P Kelly; C Pothoulakis; J T LaMont
Journal:  N Engl J Med       Date:  1994-01-27       Impact factor: 91.245

5.  Enteric infection in relapse of inflammatory bowel disease: importance of microbiological examination of stool.

Authors:  Maria Mylonaki; Louise Langmead; Athanasios Pantes; Frith Johnson; David S Rampton
Journal:  Eur J Gastroenterol Hepatol       Date:  2004-08       Impact factor: 2.566

6.  Clostridium difficile and inflammatory bowel disease.

Authors:  C Greenfield; J R Aguilar Ramirez; R E Pounder; T Williams; M Danvers; S R Marper; P Noone
Journal:  Gut       Date:  1983-08       Impact factor: 23.059

7.  Impact of Clostridium difficile on inflammatory bowel disease.

Authors:  Mazen Issa; Aravind Vijayapal; Mary Beth Graham; Dawn B Beaulieu; Mary F Otterson; Sarah Lundeen; Susan Skaros; Lydia R Weber; Richard A Komorowski; Josh F Knox; Jeanne Emmons; Jasmohan S Bajaj; David G Binion
Journal:  Clin Gastroenterol Hepatol       Date:  2007-03       Impact factor: 11.382

8.  Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease.

Authors:  A N Ananthakrishnan; E L McGinley; D G Binion
Journal:  Gut       Date:  2007-09-28       Impact factor: 23.059

9.  Clostridium difficile associated diarrhoea: a role in inflammatory bowel disease?

Authors:  R P Bolton; R J Sherriff; A E Read
Journal:  Lancet       Date:  1980-02-23       Impact factor: 79.321

10.  Occurrence of Clostridium difficile toxin during the course of inflammatory bowel disease.

Authors:  S Meyers; L Mayer; E Bottone; E Desmond; H D Janowitz
Journal:  Gastroenterology       Date:  1981-04       Impact factor: 22.682

View more
  46 in total

Review 1.  Review of medical and surgical management of Clostridium difficile infection.

Authors:  B Faris; A Blackmore; N Haboubi
Journal:  Tech Coloproctol       Date:  2010-05-08       Impact factor: 3.781

Review 2.  Quality of care delivered to hospitalized inflammatory bowel disease patients.

Authors:  Adam V Weizman; Geoffrey C Nguyen
Journal:  World J Gastroenterol       Date:  2013-10-14       Impact factor: 5.742

3.  Obesity Is Associated with Increased Risk of Colectomy in Inflammatory Bowel Disease Patients Hospitalized with Clostridium difficile Infection.

Authors:  Manish P Shrestha; Sasha Taleban
Journal:  Dig Dis Sci       Date:  2018-12-19       Impact factor: 3.199

4.  Predictors of severe outcomes associated with Clostridium difficile infection in patients with inflammatory bowel disease.

Authors:  A N Ananthakrishnan; R Guzman-Perez; V Gainer; T Cai; S Churchill; I Kohane; R M Plenge; S Murphy
Journal:  Aliment Pharmacol Ther       Date:  2012-02-23       Impact factor: 8.171

Review 5.  Defining quality indicators for best-practice management of inflammatory bowel disease in Canada.

Authors:  Geoffrey C Nguyen; Shane M Devlin; Waqqas Afif; Brian Bressler; Steven E Gruchy; Gilaad G Kaplan; Liliana Oliveira; Sophie Plamondon; Cynthia H Seow; Chadwick Williams; Karen Wong; Brian M Yan; Jennifer Jones
Journal:  Can J Gastroenterol Hepatol       Date:  2014-05

Review 6.  British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.

Authors:  Christopher Andrew Lamb; Nicholas A Kennedy; Tim Raine; Philip Anthony Hendy; Philip J Smith; Jimmy K Limdi; Bu'Hussain Hayee; Miranda C E Lomer; Gareth C Parkes; Christian Selinger; Kevin J Barrett; R Justin Davies; Cathy Bennett; Stuart Gittens; Malcolm G Dunlop; Omar Faiz; Aileen Fraser; Vikki Garrick; Paul D Johnston; Miles Parkes; Jeremy Sanderson; Helen Terry; Daniel R Gaya; Tariq H Iqbal; Stuart A Taylor; Melissa Smith; Matthew Brookes; Richard Hansen; A Barney Hawthorne
Journal:  Gut       Date:  2019-09-27       Impact factor: 23.059

Review 7.  Clostridium difficile and inflammatory bowel disease: role in pathogenesis and implications in treatment.

Authors:  Orna Nitzan; Mazen Elias; Bibiana Chazan; Raul Raz; Walid Saliba
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

8.  Ulcerative colitis worsened after Clostridium difficile infection: efficacy of infliximab.

Authors:  Andrada Seicean; Anca Moldovan-Pop; Radu Seicean
Journal:  World J Gastroenterol       Date:  2014-05-07       Impact factor: 5.742

9.  Clostridium difficile Infection: A Rarity in Patients Receiving Chronic Antibiotic Treatment for Crohn's Disease.

Authors:  Abhik Roy; Simon Lichtiger
Journal:  Inflamm Bowel Dis       Date:  2016-03       Impact factor: 5.325

Review 10.  Environmental risk factors for inflammatory bowel diseases: Evidence based literature review.

Authors:  Ayokunle T Abegunde; Bashir H Muhammad; Owais Bhatti; Tauseef Ali
Journal:  World J Gastroenterol       Date:  2016-07-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.